Jefferies Group Comments on LivaNova PLC’s Q3 2017 Earnings (LIVN)
LivaNova PLC (NASDAQ:LIVN) – Stock analysts at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for LivaNova PLC in a research report issued on Friday. Jefferies Group analyst R. Denhoy anticipates that the company will post earnings per share of $0.75 for the quarter. Jefferies Group has a “Buy” rating and a $76.00 price objective on the stock. Jefferies Group also issued estimates for LivaNova PLC’s Q4 2017 earnings at $0.82 EPS, FY2017 earnings at $3.29 EPS, FY2018 earnings at $3.63 EPS, FY2019 earnings at $4.00 EPS and FY2020 earnings at $4.42 EPS.
LIVN has been the topic of a number of other research reports. Berenberg Bank reaffirmed a “buy” rating and issued a $70.00 target price on shares of LivaNova PLC in a report on Friday, August 11th. Needham & Company LLC assumed coverage on LivaNova PLC in a report on Wednesday, August 23rd. They issued a “hold” rating on the stock. BidaskClub lowered LivaNova PLC from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, WBB Securities lowered LivaNova PLC from a “hold” rating to a “sell” rating and set a $50.00 target price on the stock. in a report on Tuesday, August 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $62.50.
LivaNova PLC (NASDAQ:LIVN) opened at 66.03 on Monday. The firm has a 50 day moving average price of $61.84 and a 200-day moving average price of $56.97. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of 117.91 and a beta of 0.58. LivaNova PLC has a 12 month low of $40.83 and a 12 month high of $66.30.
LivaNova PLC (NASDAQ:LIVN) last announced its earnings results on Wednesday, August 9th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.19. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The company had revenue of $321.40 million for the quarter, compared to analyst estimates of $315.75 million. LivaNova PLC’s revenue was up .1% on a year-over-year basis.
Several hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. lifted its position in shares of LivaNova PLC by 7.5% in the 2nd quarter. Franklin Resources Inc. now owns 5,089,070 shares of the company’s stock worth $311,515,000 after acquiring an additional 354,956 shares during the period. FMR LLC lifted its position in shares of LivaNova PLC by 74.9% in the 1st quarter. FMR LLC now owns 4,817,815 shares of the company’s stock worth $236,118,000 after acquiring an additional 2,063,196 shares during the period. BlackRock Inc. lifted its position in shares of LivaNova PLC by 79.3% in the 2nd quarter. BlackRock Inc. now owns 4,648,780 shares of the company’s stock worth $284,552,000 after acquiring an additional 2,055,891 shares during the period. State Street Corp lifted its position in shares of LivaNova PLC by 74.8% in the 2nd quarter. State Street Corp now owns 1,835,428 shares of the company’s stock worth $112,345,000 after acquiring an additional 785,268 shares during the period. Finally, Koch Industries Inc. bought a new stake in shares of LivaNova PLC in the 2nd quarter worth approximately $1,384,000. Institutional investors own 82.36% of the company’s stock.
In other LivaNova PLC news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $61.55, for a total value of $61,550.00. Following the completion of the sale, the director now owns 56,437 shares in the company, valued at approximately $3,473,697.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 3,000 shares of company stock valued at $183,110 in the last quarter. Corporate insiders own 0.28% of the company’s stock.
LivaNova PLC Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.